Research
More than 70% of breast cancer tumors express the estrogen receptor (ER), and hormonal therapy has proven effective in reducing mortality in breast cancer. Despite this, a significant risk of late recurrence remains for patients who have undergone hormonal therapy. My research aims to investigate the molecular mechanisms underlying these late recurrences, identify high-risk patients, and propose alternative treatment strategies for recurrent disease.
More specifically, I am interested in:
- Investigating the prevalence and significance of PIK3CA mutations in relation to disease progression and treatment response.
- Evaluating the prognostic and therapeutic significance of tumor-infiltrating lymphocytes (TILs) by visualizing and quantifying specific subpopulations of TILs in tumor tissue.
- Analyzing the interplay between ER, tamoxifen treatment, and the mechanisms behind what is called "tumor dormancy" in ER+ breast cancer.
​
Project Manager at Commissioned Education Office
Project manager for commissioned education at Linköping University, where I create collaboration between teachers from the Faculty of Medicine and various healthcare regions, companies, and other organizations. I help develop projects to educate and upskill professionals, with a focus on lifelong learning.
Teaching and Educational Development
I supervise medical students with their projects, facilitate online groups in the international course ONL, and work as an educational developer at Didacticum. Since 2023, I have been on the board of the Swedish network for educational development in higher education (Swednet).